non-steroidal anti-inflammatory drugs - versus control - for COVID-19 (hospitalized or not) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.94 [0.80, 1.11]< 10%4 studies (-/4)76.1 %NAnot evaluable crucial-
hospitalization 1.08 [0.71, 1.65]< 174%3 studies (-/3)36.0 %NAnot evaluable important-
mechanical ventilation 0.99 [0.66, 1.48]< 10%3 studies (-/3)52.2 %NAnot evaluable important-
ICU admission 1.13 [0.65, 1.99]< 10%2 studies (-/2)32.9 %NAnot evaluable non important-
severe COVID-19 occurrence 0.73 [0.34, 1.56]< 10%1 study (-/1)79.2 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.